1996

Novel Compounds for the Treatment of Obesity

Avraham Yosefa, HUJI, School of Medicine - IMRIC, School of Public Health
Katzhendler Z"L Jehoshua, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Berry Elliot, HUJI, School of Medicine - IMRIC, School of Public Health

Yousef Najajreh, Al Quds University

 

Reducing Body Weight and Glucose Levels  & Improving Cognitive Function

Categories

Small molecule, obesity

Development Stage

Successful demonstration of efficacy in mice

Patent Status

 US  Granted patent no. 9,428,448

Novelty and IP Status

  • The patent is covering Novel Active Compounds –derivatives of fatty acids and amino acids which may regulate feeding and body weight
  • Compound X (the leading compound) and its derivatives represent novel compounds for the treatment of obesity which do not act on either CB1, TRPV1 or PPAR-α receptors (tested by MSD for receptor binding activity).
  • The compounds present new mechanisms of action (via POMC, NPY or FAAH (Fatty Acid Amide Hydrolase) inhibition in relation to known compounds on the market: Xenical (Lipase inhibition), Reductil (NE-5HT re-uptake inhibitor) and Rimonobant (CB1 receptor antagonist) (removed recently from the market).
  • They are made of natural products which may be given orally and act in a dose-dependent manner
  • 3 compounds improve also cognitive function as well 3 compounds reduced glucose levels
  • No toxicity was found following in vivo experiments in mice ,detecting survival, neurological score and liver histopathology
  • There is a clear opportunity for  an effective and well-tolerated anti-obesity drugs. Weight loss continued for 31 days after cessation of treatment and then leveled off.

Key Features

  • Patent on new compounds which are small natural, organic molecules
  • Non toxic
  • Can be delivered orally or by injection
  • Effects resemble beneficial effects of moderate caloric restriction
  • Reduce glucose blood levels
  • Improve cognition

Development Milestones

  • Continuing studies to determine optimal dosage levels and intervals
  • Toxicology studies
  • The effect on metabolic markers for diabetes and CVD

The Opportunity

  • 1.1 billion people worldwide are suffering from the health consequences of overconsumption
  • Only one drug is currently approved for long-treatment of obesity-the lipase inhibitor Xenical. Use of this product has been limited by side effects.

 

 

Patent Status

Granted US 9,428,448

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
+972-2-6586692